Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | CALML3 | P27482 | 7/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166255 | 1.00 | MAOA (0.58) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6024297 | 1.00 | MAOA (0.58) | MAOACALML3MAOBLMNAPTGS1 | |
| Hydrochloric Acid SCHEMBL30061895 | 0.99 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6022851 | 0.97 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6022852 | 0.97 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6023931 | 0.96 | MAOA (0.61) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6023927 | 0.96 | MAOA (0.61) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6024060 | 0.93 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6024062 | 0.93 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL10197432 | 0.92 | MAOA (0.61) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635307-B1 | PHARMACEUTICAL COMPOSITIONS | MELINTA SUBSIDIARY CORP (US) | 2020-07-29 | — | — | EP | claimed |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3442526-B1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-2635307-B1 | PHARMACEUTICAL COMPOSITIONS | MELINTA SUBSIDIARY CORP (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238720-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| US-7129259-B2 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1713785-A1 | HALOGENATED BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060148869-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | CHEN SHILI | 2006-07-06 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050153971-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-07-14 | — | — | US | disclosed |
| WO-2005061468-A1 | HALOGENATED BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153971-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | PROKR1, PROKR2, PCNA | MAOA 1365/4885CALML3 4062/4885MAOB 1682/4885 |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | NCEH1, NRDC, LPL | MAOA 1440/4885CALML3 4061/4885MAOB 981/4885 |
| US-20060148869-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | PCNA, PROKR1, BCOR | MAOA 1171/4885CALML3 4101/4885MAOB 1454/4885 |
| US-20070238720-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | MAOA 707/4885CALML3 1933/4885MAOB 838/4885 |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | MAOA 707/4885CALML3 1933/4885MAOB 838/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | MAOA 379/4885CALML3 2223/4885MAOB 219/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885CALML3 4401/4885MAOB 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.